Literature DB >> 20963840

Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.

Hubert O Ballard1, Lori A Shook, Philip Bernard, Michael I Anstead, Robert Kuhn, Vicki Whitehead, Deb Grider, Timothy N Crawford, Don Hayes.   

Abstract

OBJECTIVE: Since preventive therapies for bronchopulmonary dysplasia (BPD) are limited we treated preterm infants with azithromycin to decrease the incidence of BPD.
METHODS: Infants less than 1,250 g birth weight were randomized to azithromycin or placebo within 12 hr of beginning mechanical ventilation and within 72 hr of birth. The treatment group received azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for a maximum of 6 weeks. Aspirates were collected during the study to assay for Ureaplasma. The primary endpoints were incidence of BPD or mortality. (Clinical Trials Identifier: NCT00319956.)
RESULTS: A total of 220 infants were enrolled (n=111 azithromycin, and 109 placebo). Mortality was 18% for the azithromycin group versus 22% for the placebo group (P = 0.45). Incidence of BPD was 76% for the azithromycin group versus 84% for the placebo group (P=0.2). The multiple logistic regression analysis demonstrated an odds ratio of 0.46 decrease in the chance of developing BPD or death for the azithromycin group, but was not statistically significant. The incidence of BPD in the Ureaplasma subgroup was 73% in the azithromycin group versus 94% in the placebo group (P=0.03). Analysis of patients in the Ureaplasma subgroup only, using the exact logistic model demonstrated a decrease in BPD or death in the azithromycin group with an estimated odds ratio of 0.026 (0.001-0.618, 95% confidence interval).
CONCLUSIONS: Routine use of azithromycin therapy for the prevention of BPD cannot be recommended. The early treatment of Ureaplasma colonized/infected patients might be beneficial, but a larger multi-centered trial is required to assess this more definitively.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963840     DOI: 10.1002/ppul.21352

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  28 in total

1.  Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.

Authors:  Rose M Viscardi; Ahmed A Othman; Hazem E Hassan; Natalie D Eddington; Elias Abebe; Michael L Terrin; David A Kaufman; Ken B Waites
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

2.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

3.  Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis.

Authors:  Amelia L Sutton; Edward P Acosta; Kajal B Larson; Corenna D Kerstner-Wood; Alan T Tita; Joseph R Biggio
Journal:  Am J Obstet Gynecol       Date:  2015-01-13       Impact factor: 8.661

Review 4.  An update on pharmacologic approaches to bronchopulmonary dysplasia.

Authors:  Sailaja Ghanta; Kristen Tropea Leeman; Helen Christou
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

Review 5.  Ureaplasma and BPD.

Authors:  Suhas G Kallapur; Boris W Kramer; Alan H Jobe
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

Review 6.  Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment.

Authors:  Jung S Hwang; Virender K Rehan
Journal:  Lung       Date:  2018-01-27       Impact factor: 2.584

Review 7.  Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update.

Authors:  Rose Marie Viscardi; Suhas G Kallapur
Journal:  Clin Perinatol       Date:  2015-10-09       Impact factor: 3.430

Review 8.  Ureaplasma species: role in neonatal morbidities and outcomes.

Authors:  Rose Marie Viscardi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2013-08-19       Impact factor: 5.747

9.  Role of biofilm formation in Ureaplasma antibiotic susceptibility and development of bronchopulmonary dysplasia in preterm neonates.

Authors:  Katherine Pandelidis; Amanda McCarthy; Kirsty L Chesko; Rose M Viscardi
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

10.  The association between respiratory tract Ureaplasma urealyticum colonization and severe retinopathy of prematurity in preterm infants ≤1250 g.

Authors:  R Ozdemır; F N Sarı; Z O Tunay; O Erdeve; F E Canpolat; S S Oguz; N Uras; U Dılmen
Journal:  Eye (Lond)       Date:  2012-05-04       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.